AMAG Pharmaceuticals Net debt/EBITDA
Quel est le Net debt/EBITDA de AMAG Pharmaceuticals?
Le Net debt/EBITDA de AMAG Pharmaceuticals, Inc. est -5.97
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NASDAQ par rapport à AMAG Pharmaceuticals
Que fait AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Entreprises avec net debt/ebitda similaire à AMAG Pharmaceuticals
- XLMedia PLC a Net debt/EBITDA de -5.99
- SEI Investments Co a Net debt/EBITDA de -5.99
- Beng Soon Mach Hldg Ltd a Net debt/EBITDA de -5.98
- Pacific Silk Road Resources a Net debt/EBITDA de -5.98
- Wipro a Net debt/EBITDA de -5.98
- MainStreet Bancshares Inc a Net debt/EBITDA de -5.97
- AMAG Pharmaceuticals a Net debt/EBITDA de -5.97
- Eildon Capital Fund a Net debt/EBITDA de -5.97
- CYREN Ltd a Net debt/EBITDA de -5.97
- Evolis SA a Net debt/EBITDA de -5.95
- Industria de Diseño Textil SA a Net debt/EBITDA de -5.95
- VersaBank a Net debt/EBITDA de -5.94
- 3P Learning a Net debt/EBITDA de -5.94